Description
Overview
COVIDSeq Test (RUO Version) is a next-generation sequencing (NGS) assay that enables researchers to detect and characterize novel variants of SARS-CoV-2.
Detects genome of SARS-CoV-2 RNA using ARTIC v5.4.2 primers
Supports a seamless and flexible end-to-end workflow
Rapid and scalable sequencing
The Illumina COVIDSeq Test (RUO version) accommodates 384 to 3072 samples, depending on throughput needs.
Uniform genome coverage
96 amplicons provide full coverage across SARS-CoV-2 genome for in-depth characterization of new variants.
Integrated solution
The kit includes all reagents needed for cDNA conversion, amplification, and library prep. A 63°C annealing temperature during PCR improves variant analysis and insights.
Streamlined data analysis
Assess lineage and annotate mutations with open software tools, including the Illumina DRAGEN Microbial Amplicon App in BaseSpace Sequence Hub.
Applications
The COVIDSeq Test (RUO Version) is an integrated NGS research solution for detection and characterization of SARS-CoV-2, not for use in diagnostic procedures or patient management.
Example workflow
Clarity LIMS
Illumina COVIDSeq Test (RUO Version)
NovaSeq 6000 System
NextSeq 1000/2000 Systems
NextSeq 500/550 Systems
NextSeq 550Dx System (in Research Mode)
DRAGEN Microbial Amplicon App
Related applications and methods
Coronavirus sequencing
NGS can identify novel coronavirus variants, track COVID-19 transmission, and more. Compare NGS methods for various coronavirus sequencing goals.
NGS for infectious diseases
As a hypothesis-free method, NGS can distinguish between infectious disease strains that differ by as little as one SNP, and replace the need for multiple tests.
Host genetics and immune response profiling
Studying host genetic differences and individual immune responses to the SARS-CoV-2 virus can shed light on COVID-19 disease susceptibility and severity.
Genomic coverage performance
Heat map plotting performance as a function of read length and depth shows significant improvement with paired-end reads over single reads. The fraction of genomes > 0.99 confident is shown, with values close to 1 representing more complete coverage of the SARS-CoV-2 genome.
Illumina® COVIDSeq™ Test 3072 Samples
20043675
Includes reagents for preparing 3072 samples for detection of SARS-CoV-2. Purchase IDT for Illumina-PCR Indexes Sets 1–4 separately. View less
Sign in to add to cart or see pricing.
List Price:
Discounts:
IDT® for Illumina PCR Unique Dual Indexes Set 1-4 (384 Indexes)
20043137
Set of 384 UDIs for use with Illumina® COVIDSeq™ Test View less
Showing of
Product
Qty
Unit price
Remove
Total ( items)
You have not selected any items yet.
Please add these products to your cart before leaving the page to avoid losing them.
Which Illumina sequencing systems are used for the COVIDSeq Test (RUO Version)?
The COVIDSeq Test (RUO Version) is intended for the NovaSeq 6000 Sequencing System. It can also be run on the iSeq 100, MiniSeq, MiSeq, MiSeqDx in Research Mode, NextSeq 500, NextSeq 550, NextSeq 550Dx in Research Mode, NextSeq 1000, or NextSeq 2000 Systems.
How are COVIDSeq Test (RUO) and COVIDSeq Assay (96 samples) different?
The primary difference is the number of samples each assay can run. The COVIDSeq Assay (96 samples) runs 96 samples on Illumina benchtop sequencing systems to accommodate smaller research labs. In contrast, the COVIDSeq Test (RUO) runs up to 3072 samples on the NovaSeq 6000 System or NextSeq line of sequencing systems.
What is the difference between the ARTIC v5.4.2 primer pools and prior ARTIC pools like v3 and v4?
As SARS-CoV-2 mutates, updates to the primer pools are occasionally necessary to ensure complete coverage across the genome and improved analytical sensitivity for SARS-CoV-2 variant detection. The v5.4.2 primers provide increased coverage for recent Omicron variants.
Frequently purchased
Other products to consider
